Author

Sema Sezgin Göksu

Observed names: S. S. Goksu, S. Sezgin Goksu, S. Sezgin Göksu, S.S. Goksu, SEMA SEZGIN GÖKSU, Sema Goksu, Sema S. Goksu, Sema SEZGIN GOKSU, Sema SEZGİN GÖKSU, Sema Sezgin Goksu, Sema Sezgin GÖKSU, Sema Sezin Goksu, SemaSezgin Goksu

Institution: Akdeniz University

Observed institutions: Chungbuk National University, Süleyman Demirel Üniversitesi, Yonsei University, Akdeniz University, Zhengzhou University, Peking University Cancer Hospital, Akdeniz University Hospital, Kayseri Eğitim ve Araştırma Hastanesi, Henan Cancer Hospital

ORCID: 0000-0002-8026-764X

Observed ORCID: 0000-0002-8026-764X

OpenAlex ID: A5050241263

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

2023 · Josep M Llovet, Masatoshi Kudo, et al. · The Lancet Oncology · 521

PDF

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

2024 · Ying Cheng, David R. Spigel, et al. · New England Journal of Medicine · 435

PDF

ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

2024 · David R. Spigel, Ying Cheng, et al. · Journal of Clinical Oncology · 53

Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study.

2015 · Meral Gunaldi, Sema Goksu, et al. · PubMed · 50

Extracorporeal Shock Wave Therapy for Breast Cancer–Related Lymphedema: A Pilot Study

2016 · Mehtap Aykac Cebicci, Serap Tomruk Sutbeyaz, et al. · Archives of Physical Medicine and Rehabilitation · 38

Hepatitis B reactivation related to everolimus

2013 · Sema Sezgin Göksu · World Journal of Hepatology · 37

PDF

Use of Blood Transfusion at the End of Life: Does it Have Any Effects on Survival of Cancer Patients?

2014 · Sema Sezgin Goksu, Seyda Gunduz, et al. · Asian Pacific Journal of Cancer Prevention · 31

PDF

Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

2015 · SEYDA GÜNDÜZ, SEMA SEZGIN GÖKSU, et al. · Molecular and Clinical Oncology · 26

PDF

Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age ≤35)

2014 · Sema Sezgin Goksu, Didem Tastekin, et al. · Asian Pacific Journal of Cancer Prevention · 25

PDF

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

2023 · Cengiz Karacin, Berna Oksuzoglu, et al. · BMC Cancer · 24

PDF

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

2024 · Loic Verlingue, Antoine Italiano, et al. · EBioMedicine · 23

The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

2022 · Dilek Çağlayan, Mehmet Zahid Koçak, et al. · European Journal of Clinical Pharmacology · 23

PDF

Platelet Distribution Width as a Predictor of Metastasis in Gastric Cancer Patients

2016 · Meral Gunaldi, Dilek Erdem, et al. · Journal of Gastrointestinal Cancer · 23

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

2024 · Seda Kahraman, Serdar Karakaya, et al. · Scientific Reports · 20

LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

2024 · S. Senan, D.R. Spigel, et al. · Annals of Oncology · 16

PDF

Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7thEdition Staging System

2014 · Deniz Arslan, Hakan Bozcuk, et al. · Asian Pacific Journal of Cancer Prevention · 16

68Ga-PSMA Uptake by Dermatofibroma in a Patient With Prostate Cancer

2017 · Funda Aydin, Arzu Akçal, et al. · Clinical Nuclear Medicine · 15

Major and minor salivary gland cancers: A multicenter retrospective study

2023 · Muhammet Bekir Hacioglu, Bulent Erdogan, et al. · Head & Neck · 14

PDF

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

2022 · Mustafa Gürbüz, Yasin Kutlu, et al. · Journal of Cancer Research and Clinical Oncology · 13

Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

2022 · Yusuf Ilhan, Ali Murat Tatli, et al. · International Journal of Gynecological Cancer · 13

Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen

2011 · A. M. Tatli, M. Uysal, et al. · Medical Oncology · 12

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

2023 · Çağlar Ünal, Abdulmunir Azizy, et al. · The Oncologist · 11

PDF

Pesticides and Cancer: The First Incidence Study Conducted in Turkey

2013 · Mukremin Uysal, Hakan Bozcuk, et al. · Journal of Environmental Pathology Toxicology and Oncology · 11

Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.

2014 · Mukremin Uysal, Mustafa Ozdogan, et al. · PubMed · 10

The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

2024 · Dilek Çağlayan, Mehmet Zahid Koçak, et al. · Future Oncology · 9

PDF

Works count: 107

Citation count: 1,648

H-index: 16

I10-index: 24